EFFECTIVENESS OF ENDOVASCULAR TREATMENT OF IN-STENT RESTENOSIS AFTER SUCCESSFUL CHRONIC TOTAL CORONARY OCCLUSION RECANALIZATION

Aim. To assess the effectiveness of endovascular treatment of in-stent restenosis after successful chronic total coronary occlusion (CTO) recanalization.

Methods. 117 patients who underwent successful CTO recanalization in the period from 2009 to 2012 were included in the study. All patients were referred to the elective examination including coronary angiography, intravascular ultrasound and optical coherence tomography within 6.1±0.9 months after the successful recanalization. If in-stent restenosis after CTO recanalization was confirmed and further endovascular treatment was performed, patients underwent repeat endovascular examination after 6.6±0.8 months. Сoronary artery lumen was evaluated at the sites of the performed intervention.

Results. 18.8% of patients had in-stent restenosis, of them 95.5% underwent percutaneous coronary intervention. 76.2% of patients underwent high-pressure balloon predilatation, 4.8% of patients received paclitaxel-eluting balloons, 14.2% of patients – drug-eluting stents (DES), and 4.8% of patients - bare-metal stents. A significant increase of minimum lumen diameter after the percutaneous coronary intervention (from 0.8±0.5 mm to 2.2±0.3 mm, p<0.01) and a decrease of coronary artery lumen stenosis (from 67.9±18.3% to 19.7±8.8%, p<0.01) had been determined. There were no cases of death, acute myocardial infarction, acute strokes and target lesion thrombosis 6.6±0.8 months after the in-stent restenosis treatment. 52.8% of cases had repeat restenosis, including 56.3% of those who underwent high-pressure balloon predilatation and 33.3% of patients after DES implantation. The minimum lumen diameter decreased from 2.2±0.3 mm to 1.6±0.5 mm (p<0.01), and the degree of lumen stenosis increased from 19.7±8.8 mm2 to 41.5±17.3 mm2 (p<0.01).

Conclusion. In-stent restenosis treatment after the successful CTO recanalization by the endovascular methods was effective in 47.2% of cases. DES and drug coated balloons can potentially reduce the rate of repeat restenosis.

1. DiMario C., Werner G., Sianos G., Galassi A., Büttner J., Dudek D., Chevalier B., Lefevre T., Schofer J., Koolen J., Sievert H., Reimers B., Fajadet J., Colombo A., Gershlick A., Serruys P., Reifart N. European perspective in the recanalization of Chronic Total Occlusions (CTO): consensus document from the EuroCTO Club. EuroIntervention. 2007;3(1):30-43.

2. Werner G., Martin-Yuste V., Hildick-Smith D., Boudou N., Sianos G., Gelev V., Rumoroso J.R., Erglis A., Christiansen E.H., Escaned J., di Mario C., Hovasse T., Teruel L., Bufe A., Lauer B., Bogaerts K., Goicolea J., Spratt J.C., Gershlick A.H., Galassi A.R., Louvard Y. A randomized multicentre trial to compare revascularization with optimal medical therapy for the treatment of chronic total coronary occlusions. Eur Heart J. 2018;39(26):2484-2493. doi: 10.1093/eurheartj/ehy220.

3. Wijeysundera H.C., Norris C., Fefer P., Galbraith P.D., Knudtson M.L., Wolff R., Wright G.A., Strauss B.H., Ko D.T. Relationship between initial treatment strategy and quality of life in patients with coronary chronic total occlusions. EuroIntervention. 2014;9(10):1165-1172. doi: 10.4244/EIJV9I10A197.

4. Sirnes P., Myreng Y., Molstad P., Bonarjee V., Golf S. Improvement in left ventricular ejection fraction and wall motion after successful recanalization of chronic coronary occlusions. Eur Heart J. 1998;19(2):273-281.

5. Sianos G., Konstantinidis N., Di Mario C., Karvounis H. Theory and practical based approach to chronic total occlusions. BMC Cardiovascular Disorders. 2016;16(33). Available at: https://link.springer.com/article/10.1186/s12872-016-0209-3 (Accessed 9 Feb 2016). doi: 10.1186/s12872-016-0209-3.

6. Stelmashok V.I. Risk razvitiya kardialnikh oslozhnenii pri rekanalizatsii khronicheskikh totalnikh okkluzii koronarnikh arterii antegradnim dostupom. Cardiologiya v Belarusi. 2017;4(9):747-758. (In Russian)

7. Nikolsky E., Gruberg L., Rosenblatt E., Grenadier E., Boulos M., Bernstein Z., Huber A., Gitman R., Bar-Deroma R., Markiewicz W., Beyar R. Chronic total occlusion due to diffuse in-stent restenosis: is brachytherapy the solution? Int J Cardiovasc Intervent. 2004;6(1):33-38.

8. Byrne R., Neumann F., Mehilli J., Pinieck S., Wolff B., Tiroch K., Schulz S., Fusaro M., Ott I., Ibrahim T., Hausleiter J., Valina C., Pache J., Laugwitz K., Massberg S., Kastrati A.; ISARDESIRE 3 Investigators. Paclitaxel-eluting balloons, paclitaxeleluting stents, and balloon angioplasty in patients with restenosis after implantation of a drug-eluting stent (ISAR-DESIRE 3): A randomised, open-label trial. Lancet. 2013;381(9865):461-467. doi: 10.1016/S0140-6736(12)61964-3.

9. Alfonso F., Perez-Vizcayno M., Cardenas A., Garcia Del Blanco B., Seidelberger B., Iniguez A., Gomez-Recio M., Masotti M., Velazquez M., Sanchis J., Garcia-Touchard A., Zueco J., Bethencourt A., Melgares R., Cequier A., Dominguez A., Mainar V., Lopez-Minguez J., Moreu J., Marti V., Moreno R., Jimenez-Quevedo P., Gonzalo N., Fernandez C., Macaya C.; RIBS V Study Investigators, under the auspices of the Working Group on Interventional Cardiology of the Spanish Society of Cardiology. A randomized comparison of drug-eluting balloon versus everolimus-eluting stent in patients with bare-metal stent-in-stent restenosis: The RIBS V Clinical Trial (Restenosis Intra-stent of Bare Metal Stents: Paclitaxel-eluting balloon vs. everolimus-eluting stent). JACC. 2014;63(14):1378-1386. doi: 10.1016/j.jacc.2013.12.006.

10. Isaaz K., Mayaud N., Gerbay A., Sabry M., Richard L., Cerisier A., Lamaud M., Khamis H., Abd-Alaziz A., Da Costa A. Long-Term Clinical Outcome and Routine Angiographic Followup After Successful Recanalization of Complex Coronary True Chronic Total Occlusion With a Long Stent Length: A Single-Center Experience. J Invasive Cardiol. 2013;25(7):323-329.

11. Azzalini L., Dautov R., Brilakis E., Ojeda S., Benincasa S., Bellini B., Karatasakis A., Chavarria J., Rangan B., Pan M., Carlino M., Colombo A., Rinfret S. Impact of crossing strategy on mid-term outcomes following percutaneous revascularisation of coronary chronic total occlusions. EuroIntervention. 2017;13(8):978-985. doi: 10.4244/EIJ-D-16-01010.

12. Werner G., Krack A., Schwarz G., Prochnau D., Betge S., Figulla H. Prevention of lesion recurrence in chronic total coronary occlusions by paclitaxel-eluting stents. JACC. 2004;44(12):23012306. doi: 10.1016/j.jacc.2004.09.040

13. Mehran R., Dangas G., Abizaid A., Mintz G., Lansky A., Satler L., Pichard A., Kent K., Stone G., Leon M. Angiographic patterns of in-stent restenosis: classification and implications for long-term outcome. Circulation. 1999;100(18):1872-1878.

14. Mauri L., Orav J., Candia S., Cutlip D.E., Kuntz R.E. Robustness of late lumen loss in discriminating drug-eluting stents across variable observational and randomized trials. Circulation. 2005;112(18):28332839. doi: 10.1161/CIRCULATIONAHA105.570093

15. Benjamini Y., Hochberg Y. Controlling the False Discovery Rate: A Practical and Powerful Approach to Multiple Testing. Journal of the Royal Statistical Society. 1995;57(1):289-300.

16. Watanabe H., Morimoto T., Shiomi H., Natsuaki M., Kawai K., Kozuma K., Igarashi K., Kadota K., Tanabe K., Morino Y., Hibi K., Akasaka T., Abe M., Suwa S., Muramatsu T., Kobayashi M., Dai K., Nakao K., Tarutani Y., Fujii K., Kimura T. Impact of angiographic residual stenosis on clinical outcomes after new-generation drug-eluting stents implantation: insight from a pooled analysis of the RESET and NEXT Trials. J Am Heart Assoc. 2018;7(13). pii:e008718. Available at: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6064905/ (Accessed 30 Jun 2018). doi: 10.1161/JAHA.118.008718.

17. Valenti R., Vergara R., Migliorini A., Parodi G., Carrabba N., Cerisano G., Dovellini E., Antoniucci D. Predictors of reocclusion after successful drug-eluting stent-supported percutaneous coronary intervention of chronic total occlusion. JACC. 2013;61(5):545550. doi: 10.1016/j.jacc.2012.10.036.

18. Colmenarez H., Escaned J., Fernandez C., Lobo L., Cano S., del Angel J.G., Alfonso F., Jimenez P., Bañuelos C., Gonzalo N., García E., Hernández R., Macaya C. Efficacy and Safety of Drug-Eluting Stents in Chronic Total Coronary Occlusion Recanalization. JACC. 2010;55(17):1854-1866. doi:10.1016/j.jacc.2009.12.038.

19. Levine G.N., Bates E.R., Blankenship J.C., Bailey S.R, Bittl J.A., Cercek B., Chambers C.E., Ellis S.G., Guyton R.A., Hollenberg S.M., Khot U.N., Lange R.A., Mauri L., Mehran R., Moussa I.D., Mukherjee D., Nallamothu B.K., Ting H.H. 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions. Circulation. 2011. 124(23):e574-651. doi: 10.1161/ CIR.0b013e31823ba622.

20. Sousa-Uva M., Neumann F., Ahlsson A., Alfonso F., Banning A., Benedetto U., Byrne R., Collet J., Falk V., Head S., Jüni P., Kastrati A., Koller A., Kristensen S., Niebauer J., Richter D., Seferovic P., Sibbing D., Stefanini G., Windecker S., Yadav R., Zembala M.; ESC Scientific Document Group. 2018 ESC/EACTS Guidelines on myocardial revascularization. Eur J Cardiothorac Surg. 2019. 55(1):4-90. doi: 10.1093/ejcts/ezy289.

21. Alame A., Karmpaliotis D., Alaswad K., Jaffer F., Yeh R., Wyman R.M., Patel M., Bahadorani J., Lombardi W., Grantham J.A., Kandzari D., Lembo N., Moses J., Kirtane A., Toma C., Doing A., Choi J., Uretsky B., Karacsonyi J., Resendes E., Nguyen-Trong P-K., Martinez-Parachini J.R., Karatasakis A., Danek B.A., Rangan B., Thompson C., Banerjee S., Brilakis E. Outcomes of Percutaneous Coronary Intervention in Chronic Total Occlusions Caused by In-Stent Restenosis: Insights from a U.S. Multicenter Registry. JACC. 2016;68(18, Suppl. B):B123-B124. doi: 10.1016/j.jacc.2016.09.431

22. Azzalini L., Dautov R., Ojeda S., Benincasa S., Bellini B., Giannini F., Chavarría J., Pan M., Carlino M., Colombo A., Rinfret S. Procedural and Long-Term Outcomes of Percutaneous Coronary Intervention for In-Stent Chronic Total Occlusion. JACC Cardiovasc Interv. 2017;10(9):892-902. doi: 10.1016/j.jcin.2017.01.047.

23. de la Torre Hernandez JM., Rumoroso J., Subinas A., Gonzalo N., Ojeda S., Pan M., Martín Yuste V., Suárez A., Hernández F., Teruel L., Moreu J., Cubero J.M., Cascón J.D., Vinhas H., Lozano Í., Martin Moreiras J., Pérez de Prado A., Goicolea J., Escaned J. Percutaneous intervention in chronic total coronary occlusions caused by in-stent restenosis: procedural results and long-term clinical outcomes in the TORO (Spanish registry of chronic TOtal occlusion secondary to an occlusive in-stent RestenOsis) multicentre registry. EuroIntervention. 2017;13(2):e219-e226. doi: 10.4244/EIJ-D-16-00764.

24. Elgendy I.Y., Mahmoud A.N., Elgendy A.Y., Bavry A.A. Outcomes with intravascular ultrasound-guided stent implantation: a meta-analysis of randomized trials in the era of drug-eluting stents. Circ Cardiovasc Interv. 2016;9(4):e003700. doi: 10.1161/ CIRCINTERVENTIONS.116.003700.

25. Yang Y., Mehran R, Dangas G., Reyes A., Qin J., Stone G.W., Leon M.B. Successful use of the frontrunner catheter in the treatment of in-stent coronary chronic total occlusions. Catheter Cardiovasc Interv. 2004;63(4):462-468. doi: 10.1002/ccd.20222

26. Brilakis E., Lombardi W., Banerjee S. Use of the Stingray guidewire and the Venture catheter for crossing flush coronary chronic total occlusions due to in-stent restenosis. Catheter Cardiovasc Interv. 2010;76(3):391-394. doi: 10.1002/ccd.22480.

27. Wilson W., Walsh S., Hanratty C., Strange J. A novel approach to the management of occlusive in-stent restenosis (ISR). EuroIntervention. 2014;9(11):1285-1293. doi: 10.4244/EIJV9I11A218.

28. Alfonso F., Pérez-Vizcayno M., Dutary J., Zueco J., Cequier A., García-Touchard A., Martí V., Lozano I., Angel J., Hernández J.M., López-Mínguez J.R., Melgares R., Moreno R., Seidelberger B., Fernández C., Hernandez R. Implantation of a drug-eluting stent with a different drug (switch strategy) in patients with drug-eluting stent restenosis. Results from a prospective multicenter study (RIBS III [Restenosis Intra-Stent: Balloon Angioplasty Versus Drug-Eluting Stent]). JACC Cardiovasc Interv. 2012;5(7):728-737. doi: 10.1016/j. jcin.2012.03.017.

29. Eltchaninoff H., Koning R., Tron C., Gupta V., Cribier A. Balloon angioplasty for the treatment of coronary in-stent restenosis: immediate results and 6-month angiographic recurrent restenosis rate. JACC. 1998;32(4):980-984.